San Francisco, CA, June 19, 2014 --(PR.com
)-- Leaders from big pharma will gather for the panel discussion “What Sells Big Pharma in CNS Diseases?” at the CNS Diseases World Summit, to be held September 18-19, 2014 in San Francisco, CA.
Panelists will include: Bob Bagdorf, Vice President of Worldwide Business Development at Pfizer; Shafiq Virani, Global Head of Neuroscience, Ophthalmology and Rare Disease Partnering, Hoffman-La Roche; and Virginia Smith-Swintosky, Senior Director of Scientific Licensing, Neuroscience from Johnson and Johnson. Beth Fordham-Meier, Principal & Founder of NovoCreation Consulting will moderate the panel and guide discussion.
The panel will focus on the requirements for pharma investment, as well as how these have changed with the historic challenges in CNS drug development. The panelists will share their perspectives on what criteria must be met in order for pharma to give the green light on a CNS collaboration, and how these criteria rank in importance.
The panelists will join other leaders from pharma, biotech, academia, patient advocacy groups, and government organizations at the CNS Diseases World Summit to discuss the future of the field of neuroscience. The Summit will provide a forum for delegates to discuss new ways of partnering and conducting research in order to better address the growing unmet need in neuroscience drug development.
For more information about the conference, please visit www.gtcbio.com/cnssummit2014